BioVie Inc. (BIVI) stock profile

Frequently asked questions

What does BioVie Inc. (BIVI) do?

BioVie Inc. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of drug therapies in the United States. Its pipeline includes BIV201, which completed a Phase IIa clinical trial for treating ascites due to chronic liver cirrhosis, and NE3107, which is in a Phase III clinical trial for patients with mild to moderate Alzheimer's disease and a Phase I clinical trial for Parkinson's disease. The company is also developing NE3107 in the pre-clinical stage for multiple myeloma and prostate cancer. Formerly known as NanoAntibiotics, Inc., the company changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Where is BIVI stock listed?

BioVie Inc. trades under the ticker BIVI on NASDAQ.

How can I research BIVI's financials and filings?

Vantafin provides BioVie Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the BIVI profile.